![](https://monteverdelaw.com/wp-content/uploads/case-logo/concert-pharmaceuticals-inc.png)
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE), relating to its proposed acquisition by Sun Pharmaceutical Industries Limited. Under the terms of the tender offer, CNCE shareholders are expected to receive $8.00 in cash and one non-tradeable CVR worth a deferred $3.50 in cash per share they own.